News|Articles|November 21, 2026

Moving Generalized Myasthenia Gravis Care Beyond Long-Term High-Dose Prednisone

Fact checked by: Isabella Ciccone, MPH
Listen
0:00 / 0:00

Key Takeaways

  • Diagnostic latency remains substantial in gMG due to intermittent fatigable weakness, with mean delays of 18.6 months reported among racial and ethnic minority patients.
  • Outpatient prednisone initiation at >20 mg/day was discouraged because early transient worsening can precipitate crisis, prompting earlier consideration of steroid-sparing escalation.
SHOW MORE

Karissa L. Gable, MD, and a pannel of clinicians discussed how targeted therapies are changing steroid use, bridging and treatment sequencing in generalized myasthenia gravis at an October 15, 2026, forum in Morrisville, North Carolina.

On October 15, 2026, in Morrisville, North Carolina, Karissa L. Gable, MD, of Duke Health, led a forum titled "Navigating the Evolving Landscape of Generalized Myasthenia Gravis: Strategies for FcRn Inhibitor Therapy." The discussion brought together neurologists from adult, pediatric, inpatient and private practice settings to review unmet needs in generalized myasthenia gravis (gMG), targeted therapies and treatment sequencing.

Gable opened with diagnostic delays. Because weakness in gMG is fatigable and intermittent, patients may wait up to 12 months between seeking care and diagnosis, and she cited a mean of 18.6 months among racial and ethnic minority patients.

"It can be a bit of a long diagnostic journey for some patients if their symptoms are fatigable, they're intermittent," Gable said. She added that costs concentrate in acute events, "You want to avoid having someone have an MG crisis at all costs. It's preventable."

Limiting high-dose corticosteroid exposure was a recurring theme. Gable said she starts no more than 20 mg of prednisone daily in the outpatient setting because of transient worsening in the first 7 to 10 days.

"I don't ever start anything more than 20 mg a day as an outpatient because I'm afraid I might push them into crisis accidentally," she said. When a patient needs more than 20 mg daily, she begins evaluating steroid-sparing options.

Neonatal Fc receptor (FcRn) inhibitors drew attention as a bridge while slower oral agents such as azathioprine (Imuran) and mycophenolate mofetil (CellCept), which take 6 to 9 months to work, take effect. Because FcRn inhibitors rapidly lower immunoglobulin G (IgG), "you have a really quick onset of action. It's like within a week of starting the drug, you have that IgG reduction," Gable said.

"So you have an effect immediately, whereas the other ones are kind of slowly chugging along for months on end." She estimated that she uses an FcRn inhibitor as a bridge in roughly 30% to 40% of patients who reach her clinic on prednisone after hospitalization, depending on severity. Among efgartigimod alfa (Vyvgart), rozanolixizumab (Rystiggo) and nipocalimab (Imaavy), she said, "I look at it as mostly route of preference. I kind of don't see a whole lot of difference in efficacy."

For more severe or bulbar disease, Gable leans toward the complement C5 inhibitors eculizumab (Soliris), ravulizumab (Ultomiris) and zilucoplan (Zilbrysq).

"More severe onset disease tends to respond a little better to complement inhibition, it seems like," she said, noting this reflects clinical experience rather than trial data. A case of a 54-year-old woman with diabetes (hemoglobin A1C of 7), acetylcholine receptor (AChR) antibody-positive disease and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 showed the risk of undertreatment when pyridostigmine (Mestinon) is used alone.

"This kind of symptomatology is already too bad, moderate to severe, to just use this. This will never control," Gable said. She said the choice rests on the patient's circumstances: "I try to figure out where they are in their life. Are they working? Are they traveling? Do they need something that they could take with them?"

Looking ahead, Gable pointed to platform trials combining complement and FcRn inhibition, the oral alternative pathway inhibitor iptacopan (Fabhalta), the investigational FcRn inhibitor IMVT-1402 and Descartes-08, an RNA-based chimeric antigen receptor T-cell (CAR-T) therapy that put some early patients into remission for at least a year and a half after one treatment.

"It seems kind of promising as something that could kind of reset the immune system in a sense," she said. "Where you're targeting the T cells or targeting the B cells that are producing the antibodies that are pathogenic."


Related to this article